NDC product
Naproxen Sodium Diphenhydramine Hydrochloride
NDC 21130-814 · SAFEWAY
Key facts
| Product NDC | 21130-814 |
|---|---|
| Proprietary name | Naproxen Sodium Diphenhydramine Hydrochloride |
| Nonproprietary name | Naproxen Sodium Diphenhydramine Hydrochloride |
| Substances | NAPROXEN SODIUM, DIPHENHYDRAMINE HYDROCHLORIDE |
| Dosage form | TABLET |
| Route | ORAL |
| Labeler | SAFEWAY |
| Product type | HUMAN OTC DRUG |
| Marketing category | ANDA |
| Application number | ANDA213663 |
| Pharmacologic classes | Anti-Inflammatory Agents, Non-Steroidal [CS], Cyclooxygenase Inhibitors [MoA], Histamine H1 Receptor Antagonists [MoA], Histamine-1 Receptor Antagonist [EPC], Nonsteroidal Anti-inflammatory Drug [EPC] |
| Marketing start | Jun 30, 2023 |
| Listing certified through | Dec 31, 2026 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: